Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer

Aberrant DNA methylation observed in cancer can provide survival benefits to cells by silencing genes essential for anti-tumor activity. DNA-demethylating agents such as Decitabine (DAC)/Azacitidine (AZA) activate otherwise silenced tumor suppressor genes, alter immune response and epigenetically re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado: 2017
Materias:
Acceso en línea:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_20414889_v8_n12_p_Ramakrishnan
http://hdl.handle.net/20.500.12110/paper_20414889_v8_n12_p_Ramakrishnan
Aporte de:
id paper:paper_20414889_v8_n12_p_Ramakrishnan
record_format dspace
spelling paper:paper_20414889_v8_n12_p_Ramakrishnan2023-06-08T16:33:11Z Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer beta galactosidase decitabine double stranded RNA interleukin 6 messenger RNA Notch1 receptor protein p16 transcriptome antineoplastic antimetabolite azacitidine beta galactosidase cyclin dependent kinase inhibitor 2A cytokeratin 5 decitabine IL6 protein, human interleukin 6 monoclonal antibody NOTCH1 protein, human Notch1 receptor P16 protein, human Article cancer patient cell proliferation cell size cell structure controlled study cytokine release disease marker DNA methylation drug blood level gene overexpression HT-1376 cell line human human cell MDA-MB-231/B02 cell line muscle invasive bladder cancer priority journal T24 cell line transcriptomics analogs and derivatives antagonists and inhibitors bladder tumor gene expression regulation genetic epigenesis genetics immunology metabolism pathology signal transduction smooth muscle treatment outcome tumor cell line tumor invasion Antibodies, Monoclonal Antimetabolites, Antineoplastic Azacitidine beta-Galactosidase Cell Line, Tumor Cyclin-Dependent Kinase Inhibitor p16 Epigenesis, Genetic Gene Expression Regulation, Neoplastic Humans Interleukin-6 Keratin-5 Muscle, Smooth Neoplasm Invasiveness Receptor, Notch1 Signal Transduction Treatment Outcome Urinary Bladder Neoplasms Aberrant DNA methylation observed in cancer can provide survival benefits to cells by silencing genes essential for anti-tumor activity. DNA-demethylating agents such as Decitabine (DAC)/Azacitidine (AZA) activate otherwise silenced tumor suppressor genes, alter immune response and epigenetically reprogram tumor cells. In this study, we show that non-cytotoxic nanomolar DAC concentrations modify the bladder cancer transcriptome to activate NOTCH1 at the mRNA and protein level, increase double-stranded RNA sensors and CK5-dependent differentiation. Importantly, DAC treatment increases ICN1 expression (the active intracellular domain of NOTCH1) significantly inhibiting cell proliferation and causing changes in cell size inducing morphological alterations reminiscent of senescence. These changes were not associated with β-galactosidase activity or increased p16 levels, but instead were associated with substantial IL-6 release. Increased IL-6 release was observed in both DAC-treated and ICN1 overexpressing cells as compared to control cells. Exogenous IL-6 expression was associated with a similar enlarged cell morphology that was rescued by the addition of a monoclonal antibody against IL-6. Treatment with DAC, overexpression with ICN1 or addition of exogenous IL-6 showed CK5 reduction, a surrogate marker of differentiation. Overall this study suggests that in MIBC cells, DNA hypomethylation increases NOTCH1 expression and IL-6 release to induce CK5-related differentiation. © 2017 The Author(s). 2017 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_20414889_v8_n12_p_Ramakrishnan http://hdl.handle.net/20.500.12110/paper_20414889_v8_n12_p_Ramakrishnan
institution Universidad de Buenos Aires
institution_str I-28
repository_str R-134
collection Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic beta galactosidase
decitabine
double stranded RNA
interleukin 6
messenger RNA
Notch1 receptor
protein p16
transcriptome
antineoplastic antimetabolite
azacitidine
beta galactosidase
cyclin dependent kinase inhibitor 2A
cytokeratin 5
decitabine
IL6 protein, human
interleukin 6
monoclonal antibody
NOTCH1 protein, human
Notch1 receptor
P16 protein, human
Article
cancer patient
cell proliferation
cell size
cell structure
controlled study
cytokine release
disease marker
DNA methylation
drug blood level
gene overexpression
HT-1376 cell line
human
human cell
MDA-MB-231/B02 cell line
muscle invasive bladder cancer
priority journal
T24 cell line
transcriptomics
analogs and derivatives
antagonists and inhibitors
bladder tumor
gene expression regulation
genetic epigenesis
genetics
immunology
metabolism
pathology
signal transduction
smooth muscle
treatment outcome
tumor cell line
tumor invasion
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
Azacitidine
beta-Galactosidase
Cell Line, Tumor
Cyclin-Dependent Kinase Inhibitor p16
Epigenesis, Genetic
Gene Expression Regulation, Neoplastic
Humans
Interleukin-6
Keratin-5
Muscle, Smooth
Neoplasm Invasiveness
Receptor, Notch1
Signal Transduction
Treatment Outcome
Urinary Bladder Neoplasms
spellingShingle beta galactosidase
decitabine
double stranded RNA
interleukin 6
messenger RNA
Notch1 receptor
protein p16
transcriptome
antineoplastic antimetabolite
azacitidine
beta galactosidase
cyclin dependent kinase inhibitor 2A
cytokeratin 5
decitabine
IL6 protein, human
interleukin 6
monoclonal antibody
NOTCH1 protein, human
Notch1 receptor
P16 protein, human
Article
cancer patient
cell proliferation
cell size
cell structure
controlled study
cytokine release
disease marker
DNA methylation
drug blood level
gene overexpression
HT-1376 cell line
human
human cell
MDA-MB-231/B02 cell line
muscle invasive bladder cancer
priority journal
T24 cell line
transcriptomics
analogs and derivatives
antagonists and inhibitors
bladder tumor
gene expression regulation
genetic epigenesis
genetics
immunology
metabolism
pathology
signal transduction
smooth muscle
treatment outcome
tumor cell line
tumor invasion
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
Azacitidine
beta-Galactosidase
Cell Line, Tumor
Cyclin-Dependent Kinase Inhibitor p16
Epigenesis, Genetic
Gene Expression Regulation, Neoplastic
Humans
Interleukin-6
Keratin-5
Muscle, Smooth
Neoplasm Invasiveness
Receptor, Notch1
Signal Transduction
Treatment Outcome
Urinary Bladder Neoplasms
Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer
topic_facet beta galactosidase
decitabine
double stranded RNA
interleukin 6
messenger RNA
Notch1 receptor
protein p16
transcriptome
antineoplastic antimetabolite
azacitidine
beta galactosidase
cyclin dependent kinase inhibitor 2A
cytokeratin 5
decitabine
IL6 protein, human
interleukin 6
monoclonal antibody
NOTCH1 protein, human
Notch1 receptor
P16 protein, human
Article
cancer patient
cell proliferation
cell size
cell structure
controlled study
cytokine release
disease marker
DNA methylation
drug blood level
gene overexpression
HT-1376 cell line
human
human cell
MDA-MB-231/B02 cell line
muscle invasive bladder cancer
priority journal
T24 cell line
transcriptomics
analogs and derivatives
antagonists and inhibitors
bladder tumor
gene expression regulation
genetic epigenesis
genetics
immunology
metabolism
pathology
signal transduction
smooth muscle
treatment outcome
tumor cell line
tumor invasion
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
Azacitidine
beta-Galactosidase
Cell Line, Tumor
Cyclin-Dependent Kinase Inhibitor p16
Epigenesis, Genetic
Gene Expression Regulation, Neoplastic
Humans
Interleukin-6
Keratin-5
Muscle, Smooth
Neoplasm Invasiveness
Receptor, Notch1
Signal Transduction
Treatment Outcome
Urinary Bladder Neoplasms
description Aberrant DNA methylation observed in cancer can provide survival benefits to cells by silencing genes essential for anti-tumor activity. DNA-demethylating agents such as Decitabine (DAC)/Azacitidine (AZA) activate otherwise silenced tumor suppressor genes, alter immune response and epigenetically reprogram tumor cells. In this study, we show that non-cytotoxic nanomolar DAC concentrations modify the bladder cancer transcriptome to activate NOTCH1 at the mRNA and protein level, increase double-stranded RNA sensors and CK5-dependent differentiation. Importantly, DAC treatment increases ICN1 expression (the active intracellular domain of NOTCH1) significantly inhibiting cell proliferation and causing changes in cell size inducing morphological alterations reminiscent of senescence. These changes were not associated with β-galactosidase activity or increased p16 levels, but instead were associated with substantial IL-6 release. Increased IL-6 release was observed in both DAC-treated and ICN1 overexpressing cells as compared to control cells. Exogenous IL-6 expression was associated with a similar enlarged cell morphology that was rescued by the addition of a monoclonal antibody against IL-6. Treatment with DAC, overexpression with ICN1 or addition of exogenous IL-6 showed CK5 reduction, a surrogate marker of differentiation. Overall this study suggests that in MIBC cells, DNA hypomethylation increases NOTCH1 expression and IL-6 release to induce CK5-related differentiation. © 2017 The Author(s).
title Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer
title_short Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer
title_full Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer
title_fullStr Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer
title_full_unstemmed Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer
title_sort decitabine, a dna-demethylating agent, promotes differentiation via notch1 signaling and alters immune-related pathways in muscle-invasive bladder cancer
publishDate 2017
url https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_20414889_v8_n12_p_Ramakrishnan
http://hdl.handle.net/20.500.12110/paper_20414889_v8_n12_p_Ramakrishnan
_version_ 1768542478511636480